Data Source & Methodology
About This Analysis
This analysis examines data collected through voluntary reports submitted to ZorbiumLawsuit.com between March 2024 and July 2025. All cases were self-reported by pet owners who experienced adverse events following Zorbium® administration to their pets.
Data Collection
Data was collected through a structured form on our website where pet owners voluntarily reported adverse events experienced by their pets following Zorbium® administration. The form captured information including:
- Pet demographics (species, breed, age, weight, gender)
- Administration details (date, reason, timing, dosage)
- Reported symptoms and outcomes
- Veterinary provider information
- Whether the pet survived the adverse event
Data Processing
For this analysis:
- Reports were compiled between March 2024 and July 2025
- Obvious duplicate submissions were consolidated
- Incomplete reports were included when they contained essential information about symptoms and outcomes
- No reports were excluded based on the severity of the adverse event
- All reports were treated as individual cases for statistical purposes
Limitations
We acknowledge several important limitations of this dataset:
- Self-Reported Data: All information was provided by pet owners rather than veterinary professionals, which may affect medical accuracy.
- Selection Bias: Pet owners who experienced adverse events, particularly severe ones, are more likely to find and report to our website.
- No Denominator: Without knowledge of the total number of Zorbium® administrations, we cannot calculate true incidence rates.
- Verification Challenges: While we have no reason to doubt submitted reports, we cannot independently verify medical details.
- Reporting Inconsistencies: The level of detail in reports varies considerably.
Despite these limitations, the consistency of symptoms and outcomes across numerous cases from different geographic areas suggests patterns that warrant attention. This analysis represents our best effort to identify these patterns while acknowledging the inherent constraints of the data source.
Purpose
The purpose of this analysis is not to make definitive claims about Zorbium®’s safety profile, but rather to:
- Document patterns emerging from reported cases
- Raise awareness of potential adverse events
- Highlight areas that require further investigation
- Advocate for greater transparency and informed consent
We encourage veterinary professionals, regulatory agencies, and the drug manufacturer to conduct more rigorous investigations based on comprehensive data.